Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Completed Not applicable Interventional Results available

Clinical Evaluation of a Cochlear Implant Sound Processor

NCT04237207
View directory record Official record
Conditions
Hearing Loss, Ear Diseases, Hearing Disorders, Otorhinolaryngologic Diseases
Interventions
Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software, 301-M062 sound processor & software
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Tampa, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536
View directory record Official record
Conditions
Epilepsy
Interventions
Progesterone Lozenges, Matched Placebo Lozenges
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 23, 2026, 9:22 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

NCT00979004
View directory record Official record
Conditions
Epilepsy
Interventions
ICA-105665
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Little Rock, Arkansas • Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 23, 2026, 9:22 AM EDT
Not yet recruiting Not applicable Interventional

High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years

NCT07803692
View directory record Official record
Conditions
Idiopathic Generalized Epilepsy
Interventions
Intervention 1, Intervention 2
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Hormone Replacement in Menopausal Women With Epilepsy

NCT00027209
View directory record Official record
Conditions
Menopause, Epilepsy
Interventions
prempro
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency

NCT00246870
View directory record Official record
Conditions
Succinic Semialdehyde Dehydrogenase Deficiency, SSADH Deficiency
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
5 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Telephone-Based Support Programs for People With Epilepsy

NCT05082181
View directory record Official record
Conditions
Epilepsy
Interventions
UPLIFT (Using Practice and Learning to Increase Favorable Thoughts), BOOST (Bringing Out Our Strength Together)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Validating a Self-fitting Hearing Aid

NCT05246904
View directory record Official record
Conditions
Hearing and Vision Loss
Interventions
Fitting algorithm
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

NCT05438641
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
BZDP-Sparing Protocol, BZDP-Based Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

NCT05059327
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
5 Years to 30 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Putting Electroencephalography (EEG) in the Emergency Department

NCT01671475
View directory record Official record
Conditions
Altered Mental Status
Interventions
microEEG (Bio-Signal microEEG)
Device
Lead sponsor
Bio-Signal Group Corp.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Brooklyn, New York • Brookyln, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Electrical Brain Stimulation to Reduce Epileptic Seizures

NCT00344877
View directory record Official record
Conditions
Temporal Lobe Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Magnetoencephalography in Absence Seizures

NCT00884351
View directory record Official record
Conditions
Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
7 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

NCT00001489
View directory record Official record
Conditions
Epilepsy, Epilepsy, Complex Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated Not applicable Interventional

Transnasal Induction of Normothermia for Neurogenic Fever

NCT06038513
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Seizures, Metabolic Encephalopathy
Interventions
Transnasal Thermal Regulating Device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 9:22 AM EDT